#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=HIV/AIDS continues to be one of the most challenging individual and public health concerns of our days .
1-1	0-8	HIV/AIDS	abstract	new	coref	11-22
1-2	9-18	continues	_	_	_	_
1-3	19-21	to	_	_	_	_
1-4	22-24	be	_	_	_	_
1-5	25-28	one	abstract[2]	new[2]	_	_
1-6	29-31	of	abstract[2]	new[2]	_	_
1-7	32-35	the	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-8	36-40	most	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-9	41-52	challenging	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-10	53-63	individual	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-11	64-67	and	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-12	68-74	public	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-13	75-81	health	abstract[2]|abstract|abstract[4]	new[2]|new|new[4]	_	_
1-14	82-90	concerns	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-15	91-93	of	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-16	94-97	our	abstract[2]|abstract[4]|person|time[6]	new[2]|new[4]|acc|new[6]	_	_
1-17	98-102	days	abstract[2]|abstract[4]|time[6]	new[2]|new[4]|new[6]	_	_
1-18	103-104	.	_	_	_	_

#Text=According to the latest UNAIDS data , in 2018 , roughly 37.9 million individuals were infected with HIV globally , while around 770,000 people died of AIDS-related illness .
2-1	105-114	According	_	_	_	_
2-2	115-117	to	_	_	_	_
2-3	118-121	the	abstract[8]	new[8]	_	_
2-4	122-128	latest	abstract[8]	new[8]	_	_
2-5	129-135	UNAIDS	organization|abstract[8]	new|new[8]	_	_
2-6	136-140	data	abstract[8]	new[8]	_	_
2-7	141-142	,	_	_	_	_
2-8	143-145	in	_	_	_	_
2-9	146-150	2018	time	new	_	_
2-10	151-152	,	_	_	_	_
2-11	153-160	roughly	person[10]	new[10]	_	_
2-12	161-165	37.9	person[10]	new[10]	_	_
2-13	166-173	million	person[10]	new[10]	_	_
2-14	174-185	individuals	person[10]	new[10]	_	_
2-15	186-190	were	_	_	_	_
2-16	191-199	infected	_	_	_	_
2-17	200-204	with	_	_	_	_
2-18	205-208	HIV	abstract	new	coref	9-19
2-19	209-217	globally	_	_	_	_
2-20	218-219	,	_	_	_	_
2-21	220-225	while	_	_	_	_
2-22	226-232	around	person[12]	new[12]	_	_
2-23	233-240	770,000	person[12]	new[12]	_	_
2-24	241-247	people	person[12]	new[12]	_	_
2-25	248-252	died	_	_	_	_
2-26	253-255	of	_	_	_	_
2-27	256-268	AIDS-related	event[13]	new[13]	_	_
2-28	269-276	illness	event[13]	new[13]	_	_
2-29	277-278	.	_	_	_	_

#Text=During that same year , an estimated 1.7 million new infections occurred , mainly due to unprotected sexual intercourse .
3-1	279-285	During	_	_	_	_
3-2	286-290	that	time[14]	new[14]	_	_
3-3	291-295	same	time[14]	new[14]	_	_
3-4	296-300	year	time[14]	new[14]	_	_
3-5	301-302	,	_	_	_	_
3-6	303-305	an	event[15]	new[15]	coref	9-17[58_15]
3-7	306-315	estimated	event[15]	new[15]	_	_
3-8	316-319	1.7	event[15]	new[15]	_	_
3-9	320-327	million	event[15]	new[15]	_	_
3-10	328-331	new	event[15]	new[15]	_	_
3-11	332-342	infections	event[15]	new[15]	_	_
3-12	343-351	occurred	_	_	_	_
3-13	352-353	,	_	_	_	_
3-14	354-360	mainly	event[16]	new[16]	_	_
3-15	361-364	due	event[16]	new[16]	_	_
3-16	365-367	to	event[16]	new[16]	_	_
3-17	368-379	unprotected	event[16]	new[16]	_	_
3-18	380-386	sexual	event[16]	new[16]	_	_
3-19	387-398	intercourse	event[16]	new[16]	_	_
3-20	399-400	.	_	_	_	_

#Text=Investment in the field has been considerable , but a cure to the infection remains elusive .
4-1	401-411	Investment	abstract[17]	new[17]	_	_
4-2	412-414	in	abstract[17]	new[17]	_	_
4-3	415-418	the	abstract[17]|abstract[18]	new[17]|new[18]	coref	8-9[49_18]
4-4	419-424	field	abstract[17]|abstract[18]	new[17]|new[18]	_	_
4-5	425-428	has	_	_	_	_
4-6	429-433	been	_	_	_	_
4-7	434-446	considerable	_	_	_	_
4-8	447-448	,	_	_	_	_
4-9	449-452	but	_	_	_	_
4-10	453-454	a	event[19]	new[19]	_	_
4-11	455-459	cure	event[19]	new[19]	_	_
4-12	460-462	to	event[19]	new[19]	_	_
4-13	463-466	the	event[19]|abstract[20]	new[19]|new[20]	coref	6-38[0_20]
4-14	467-476	infection	event[19]|abstract[20]	new[19]|new[20]	_	_
4-15	477-484	remains	_	_	_	_
4-16	485-492	elusive	_	_	_	_
4-17	493-494	.	_	_	_	_

#Text=Nonetheless , tremendous advances have been made over the last 36 years since HIV-1 was identified , namely in prevention , diagnostics , and treatment .
5-1	495-506	Nonetheless	_	_	_	_
5-2	507-508	,	_	_	_	_
5-3	509-519	tremendous	abstract[21]	new[21]	_	_
5-4	520-528	advances	abstract[21]	new[21]	_	_
5-5	529-533	have	_	_	_	_
5-6	534-538	been	_	_	_	_
5-7	539-543	made	_	_	_	_
5-8	544-548	over	_	_	_	_
5-9	549-552	the	time[22]	new[22]	_	_
5-10	553-557	last	time[22]	new[22]	_	_
5-11	558-560	36	time[22]	new[22]	_	_
5-12	561-566	years	time[22]	new[22]	_	_
5-13	567-572	since	_	_	_	_
5-14	573-578	HIV-1	abstract	new	_	_
5-15	579-582	was	_	_	_	_
5-16	583-593	identified	_	_	_	_
5-17	594-595	,	_	_	_	_
5-18	596-602	namely	abstract[24]	new[24]	coref	8-10[0_24]
5-19	603-605	in	abstract[24]	new[24]	_	_
5-20	606-616	prevention	abstract[24]	new[24]	_	_
5-21	617-618	,	_	_	_	_
5-22	619-630	diagnostics	abstract	new	_	_
5-23	631-632	,	_	_	_	_
5-24	633-636	and	_	_	_	_
5-25	637-646	treatment	abstract	new	coref	9-1[52_0]
5-26	647-648	.	_	_	_	_

#Text=The development of antiretroviral drugs and the introduction of highly active antiretroviral therapy ( HAART ) in the mid-1990s — currently referred to as combination antiretroviral therapy ( cART ) — led to a dramatic shift of AIDS from a fatal disease into a chronic and often stable medical condition .
6-1	649-652	The	event[27]	new[27]	_	_
6-2	653-664	development	event[27]	new[27]	_	_
6-3	665-667	of	event[27]	new[27]	_	_
6-4	668-682	antiretroviral	event[27]|substance[28]	new[27]|new[28]	coref	8-1[47_28]
6-5	683-688	drugs	event[27]|substance[28]	new[27]|new[28]	_	_
6-6	689-692	and	_	_	_	_
6-7	693-696	the	event[29]	new[29]	_	_
6-8	697-709	introduction	event[29]	new[29]	_	_
6-9	710-712	of	event[29]	new[29]	_	_
6-10	713-719	highly	event[29]|abstract[30]	new[29]|new[30]	appos	6-15[0_30]
6-11	720-726	active	event[29]|abstract[30]	new[29]|new[30]	_	_
6-12	727-741	antiretroviral	event[29]|abstract[30]	new[29]|new[30]	_	_
6-13	742-749	therapy	event[29]|abstract[30]	new[29]|new[30]	_	_
6-14	750-751	(	event[29]	new[29]	_	_
6-15	752-757	HAART	event[29]|abstract	new[29]|giv	coref	6-25[35_0]
6-16	758-759	)	event[29]	new[29]	_	_
6-17	760-762	in	event[29]	new[29]	_	_
6-18	763-766	the	event[29]|time[32]	new[29]|new[32]	_	_
6-19	767-776	mid-1990s	event[29]|time[32]	new[29]|new[32]	_	_
6-20	777-778	—	_	_	_	_
6-21	779-788	currently	_	_	_	_
6-22	789-797	referred	_	_	_	_
6-23	798-800	to	_	_	_	_
6-24	801-803	as	_	_	_	_
6-25	804-815	combination	abstract|abstract[35]	new|giv[35]	appos|coref	6-29[0_35]|18-25[168_0]
6-26	816-830	antiretroviral	abstract|abstract[35]	new|giv[35]	_	_
6-27	831-838	therapy	abstract[35]	giv[35]	_	_
6-28	839-840	(	_	_	_	_
6-29	841-845	cART	abstract	giv	coref	7-4
6-30	846-847	)	_	_	_	_
6-31	848-849	—	_	_	_	_
6-32	850-853	led	_	_	_	_
6-33	854-856	to	_	_	_	_
6-34	857-858	a	event[37]	new[37]	_	_
6-35	859-867	dramatic	event[37]	new[37]	_	_
6-36	868-873	shift	event[37]	new[37]	_	_
6-37	874-876	of	event[37]	new[37]	_	_
6-38	877-881	AIDS	event[37]|abstract	new[37]|giv	coref	18-22[167_0]
6-39	882-886	from	event[37]	new[37]	_	_
6-40	887-888	a	event[37]|abstract[39]	new[37]|new[39]	_	_
6-41	889-894	fatal	event[37]|abstract[39]	new[37]|new[39]	_	_
6-42	895-902	disease	event[37]|abstract[39]	new[37]|new[39]	_	_
6-43	903-907	into	_	_	_	_
6-44	908-909	a	abstract[40]	new[40]	_	_
6-45	910-917	chronic	abstract[40]	new[40]	_	_
6-46	918-921	and	abstract[40]	new[40]	_	_
6-47	922-927	often	abstract[40]	new[40]	_	_
6-48	928-934	stable	abstract[40]	new[40]	_	_
6-49	935-942	medical	abstract[40]	new[40]	_	_
6-50	943-952	condition	abstract[40]	new[40]	_	_
6-51	953-954	.	_	_	_	_

#Text=In fact , cART contributed decisively to a steady decrease in the number of HIV-related deaths since the first years of the new millennium .
7-1	955-957	In	_	_	_	_
7-2	958-962	fact	_	_	_	_
7-3	963-964	,	_	_	_	_
7-4	965-969	cART	abstract	giv	coref	11-1[67_0]
7-5	970-981	contributed	_	_	_	_
7-6	982-992	decisively	_	_	_	_
7-7	993-995	to	_	_	_	_
7-8	996-997	a	event[42]	new[42]	_	_
7-9	998-1004	steady	event[42]	new[42]	_	_
7-10	1005-1013	decrease	event[42]	new[42]	_	_
7-11	1014-1016	in	event[42]	new[42]	_	_
7-12	1017-1020	the	event[42]|abstract[43]	new[42]|new[43]	_	_
7-13	1021-1027	number	event[42]|abstract[43]	new[42]|new[43]	_	_
7-14	1028-1030	of	event[42]|abstract[43]	new[42]|new[43]	_	_
7-15	1031-1042	HIV-related	event[42]|abstract[43]|event[44]	new[42]|new[43]|new[44]	_	_
7-16	1043-1049	deaths	event[42]|abstract[43]|event[44]	new[42]|new[43]|new[44]	_	_
7-17	1050-1055	since	_	_	_	_
7-18	1056-1059	the	time[45]	new[45]	_	_
7-19	1060-1065	first	time[45]	new[45]	_	_
7-20	1066-1071	years	time[45]	new[45]	_	_
7-21	1072-1074	of	time[45]	new[45]	_	_
7-22	1075-1078	the	time[45]|time[46]	new[45]|new[46]	_	_
7-23	1079-1082	new	time[45]|time[46]	new[45]|new[46]	_	_
7-24	1083-1093	millennium	time[45]|time[46]	new[45]|new[46]	_	_
7-25	1094-1095	.	_	_	_	_

#Text=Antiretroviral drugs have also been found useful in the prevention field , particularly in post-exposure prophylaxis or mother-to-child transmission .
8-1	1096-1110	Antiretroviral	substance[47]	giv[47]	_	_
8-2	1111-1116	drugs	substance[47]	giv[47]	_	_
8-3	1117-1121	have	_	_	_	_
8-4	1122-1126	also	_	_	_	_
8-5	1127-1131	been	_	_	_	_
8-6	1132-1137	found	_	_	_	_
8-7	1138-1144	useful	_	_	_	_
8-8	1145-1147	in	_	_	_	_
8-9	1148-1151	the	abstract[49]	giv[49]	coref	17-15[151_49]
8-10	1152-1162	prevention	abstract|abstract[49]	giv|giv[49]	coref	9-3
8-11	1163-1168	field	abstract[49]	giv[49]	_	_
8-12	1169-1170	,	_	_	_	_
8-13	1171-1183	particularly	abstract[50]	new[50]	coref	9-5[54_50]
8-14	1184-1186	in	abstract[50]	new[50]	_	_
8-15	1187-1200	post-exposure	abstract[50]	new[50]	_	_
8-16	1201-1212	prophylaxis	abstract[50]	new[50]	_	_
8-17	1213-1215	or	_	_	_	_
8-18	1216-1231	mother-to-child	event[51]	new[51]	coref	12-57[90_51]
8-19	1232-1244	transmission	event[51]	new[51]	_	_
8-20	1245-1246	.	_	_	_	_

#Text=Treatment as prevention and pre-exposure prophylaxis ( PrEP ) have further contributed to the reduction of sexually transmitted HIV infections .
9-1	1247-1256	Treatment	abstract[52]	giv[52]	_	_
9-2	1257-1259	as	abstract[52]	giv[52]	_	_
9-3	1260-1270	prevention	abstract[52]|abstract	giv[52]|giv	coref	10-25
9-4	1271-1274	and	abstract[52]	giv[52]	_	_
9-5	1275-1287	pre-exposure	abstract[52]|abstract[54]	giv[52]|giv[54]	appos	9-8[0_54]
9-6	1288-1299	prophylaxis	abstract[52]|abstract[54]	giv[52]|giv[54]	_	_
9-7	1300-1301	(	_	_	_	_
9-8	1302-1306	PrEP	abstract	giv	coref	12-38[84_0]
9-9	1307-1308	)	_	_	_	_
9-10	1309-1313	have	_	_	_	_
9-11	1314-1321	further	_	_	_	_
9-12	1322-1333	contributed	_	_	_	_
9-13	1334-1336	to	_	_	_	_
9-14	1337-1340	the	abstract[56]	new[56]	_	_
9-15	1341-1350	reduction	abstract[56]	new[56]	_	_
9-16	1351-1353	of	abstract[56]	new[56]	_	_
9-17	1354-1362	sexually	abstract[56]|event[58]	new[56]|giv[58]	_	_
9-18	1363-1374	transmitted	abstract[56]|event[58]	new[56]|giv[58]	_	_
9-19	1375-1378	HIV	abstract[56]|abstract|event[58]	new[56]|giv|giv[58]	coref	18-22
9-20	1379-1389	infections	abstract[56]|event[58]	new[56]|giv[58]	_	_
9-21	1390-1391	.	_	_	_	_

#Text=Long-lasting injectable products and antiretroviral-based microbicides that are currently in late stages of clinical development or regulatory approval may soon provide new options for prevention .
10-1	1392-1404	Long-lasting	object[59]|abstract[60]	new[59]|new[60]	coref|coref	12-139[112_59]|12-139[113_60]
10-2	1405-1415	injectable	object[59]|abstract[60]	new[59]|new[60]	_	_
10-3	1416-1424	products	object[59]|abstract[60]	new[59]|new[60]	_	_
10-4	1425-1428	and	abstract[60]	new[60]	_	_
10-5	1429-1449	antiretroviral-based	abstract[60]|substance[61]	new[60]|new[61]	_	_
10-6	1450-1462	microbicides	abstract[60]|substance[61]	new[60]|new[61]	_	_
10-7	1463-1467	that	abstract[60]|substance[61]	new[60]|new[61]	_	_
10-8	1468-1471	are	abstract[60]|substance[61]	new[60]|new[61]	_	_
10-9	1472-1481	currently	abstract[60]|substance[61]|time[62]	new[60]|new[61]|new[62]	_	_
10-10	1482-1484	in	abstract[60]|substance[61]|time[62]	new[60]|new[61]|new[62]	_	_
10-11	1485-1489	late	abstract[60]|substance[61]|time[62]	new[60]|new[61]|new[62]	_	_
10-12	1490-1496	stages	abstract[60]|substance[61]|time[62]	new[60]|new[61]|new[62]	_	_
10-13	1497-1499	of	abstract[60]|substance[61]|time[62]	new[60]|new[61]|new[62]	_	_
10-14	1500-1508	clinical	abstract[60]|substance[61]|time[62]|abstract[63]	new[60]|new[61]|new[62]|new[63]	_	_
10-15	1509-1520	development	abstract[60]|substance[61]|time[62]|abstract[63]	new[60]|new[61]|new[62]|new[63]	_	_
10-16	1521-1523	or	abstract[60]|substance[61]|time[62]	new[60]|new[61]|new[62]	_	_
10-17	1524-1534	regulatory	abstract[60]|substance[61]|time[62]|event[64]	new[60]|new[61]|new[62]|new[64]	_	_
10-18	1535-1543	approval	abstract[60]|substance[61]|time[62]|event[64]	new[60]|new[61]|new[62]|new[64]	_	_
10-19	1544-1547	may	_	_	_	_
10-20	1548-1552	soon	_	_	_	_
10-21	1553-1560	provide	_	_	_	_
10-22	1561-1564	new	abstract[65]	new[65]	_	_
10-23	1565-1572	options	abstract[65]	new[65]	_	_
10-24	1573-1576	for	abstract[65]	new[65]	_	_
10-25	1577-1587	prevention	abstract[65]|abstract	new[65]|giv	_	_
10-26	1588-1589	.	_	_	_	_

#Text=Gene therapy and the use of broadly neutralizing antibodies are also attracting a great deal of interest as possible approaches to HIV/AIDS management .
11-1	1590-1594	Gene	abstract[67]|abstract[68]	giv[67]|new[68]	coref|coref	12-36[0_67]|16-4[145_68]
11-2	1595-1602	therapy	abstract[67]|abstract[68]	giv[67]|new[68]	_	_
11-3	1603-1606	and	abstract[68]	new[68]	_	_
11-4	1607-1610	the	abstract[68]|event[69]	new[68]|new[69]	_	_
11-5	1611-1614	use	abstract[68]|event[69]	new[68]|new[69]	_	_
11-6	1615-1617	of	abstract[68]|event[69]	new[68]|new[69]	_	_
11-7	1618-1625	broadly	abstract[68]|event[69]|substance[70]	new[68]|new[69]|new[70]	_	_
11-8	1626-1638	neutralizing	abstract[68]|event[69]|substance[70]	new[68]|new[69]|new[70]	_	_
11-9	1639-1649	antibodies	abstract[68]|event[69]|substance[70]	new[68]|new[69]|new[70]	_	_
11-10	1650-1653	are	_	_	_	_
11-11	1654-1658	also	_	_	_	_
11-12	1659-1669	attracting	_	_	_	_
11-13	1670-1671	a	abstract[71]	new[71]	_	_
11-14	1672-1677	great	abstract[71]	new[71]	_	_
11-15	1678-1682	deal	abstract[71]	new[71]	_	_
11-16	1683-1685	of	abstract[71]	new[71]	_	_
11-17	1686-1694	interest	abstract[71]	new[71]	_	_
11-18	1695-1697	as	_	_	_	_
11-19	1698-1706	possible	abstract[72]	new[72]	coref	16-1[143_72]
11-20	1707-1717	approaches	abstract[72]	new[72]	_	_
11-21	1718-1720	to	abstract[72]	new[72]	_	_
11-22	1721-1729	HIV/AIDS	abstract[72]|abstract|abstract[74]	new[72]|giv|new[74]	_	_
11-23	1730-1740	management	abstract[72]|abstract[74]	new[72]|new[74]	_	_
11-24	1741-1742	.	_	_	_	_

#Text=Still , different challenges remain in anti-HIV drug therapy/prophylaxis , and these include the following , among others : ( i ) the onset of severe adverse effects leading to the discontinuation or interruption of therapy or even prophylaxis ; ( ii ) sub-optimal biodistribution and pharmacokinetics , particularly in reservoir sites or mucosae involved in sexual transmission ; ( iii ) the occurrence of viral resistance ; ( iv ) troublesome regimens and/or drug delivery routes that lead to poor adherence by patients/users ; ( v ) low stability and reduced shelf-life of active molecules , which may be particularly challenging in tropical climates and low-resource regions lacking adequate refrigerated distribution channels and storage ; ( vi ) lack of suitable dosage forms for particular populations ( e.g. , children and women ) ; ( vii ) costly drug products that are often inaccessible to populations in need of therapy/prophylaxis ; and ( viii ) social and legal constraints resulting in poor access to and the discontinuation of anti-HIV therapy/prophylaxis .
12-1	1743-1748	Still	_	_	_	_
12-2	1749-1750	,	_	_	_	_
12-3	1751-1760	different	abstract[75]	new[75]	ana	12-12[0_75]
12-4	1761-1771	challenges	abstract[75]	new[75]	_	_
12-5	1772-1778	remain	_	_	_	_
12-6	1779-1781	in	_	_	_	_
12-7	1782-1790	anti-HIV	abstract[77]	new[77]	coref	12-151[0_77]
12-8	1791-1795	drug	substance|abstract[77]	new|new[77]	coref	12-75
12-9	1796-1815	therapy/prophylaxis	abstract[77]	new[77]	_	_
12-10	1816-1817	,	_	_	_	_
12-11	1818-1821	and	_	_	_	_
12-12	1822-1827	these	abstract	giv	coref	14-18[128_0]
12-13	1828-1835	include	_	_	_	_
12-14	1836-1839	the	_	_	_	_
12-15	1840-1849	following	_	_	_	_
12-16	1850-1851	,	_	_	_	_
12-17	1852-1857	among	_	_	_	_
12-18	1858-1864	others	event[79]	new[79]	_	_
12-19	1865-1866	:	event[79]	new[79]	_	_
12-20	1867-1868	(	event[79]	new[79]	_	_
12-21	1869-1870	i	event[79]	new[79]	_	_
12-22	1871-1872	)	event[79]	new[79]	_	_
12-23	1873-1876	the	event[79]	new[79]	_	_
12-24	1877-1882	onset	event[79]	new[79]	_	_
12-25	1883-1885	of	event[79]	new[79]	_	_
12-26	1886-1892	severe	event[79]|abstract[80]	new[79]|new[80]	_	_
12-27	1893-1900	adverse	event[79]|abstract[80]	new[79]|new[80]	_	_
12-28	1901-1908	effects	event[79]|abstract[80]	new[79]|new[80]	_	_
12-29	1909-1916	leading	event[79]|abstract[80]	new[79]|new[80]	_	_
12-30	1917-1919	to	event[79]|abstract[80]	new[79]|new[80]	_	_
12-31	1920-1923	the	event[79]|abstract[80]|event[81]	new[79]|new[80]|new[81]	coref	12-167[119_81]
12-32	1924-1939	discontinuation	event[79]|abstract[80]|event[81]	new[79]|new[80]|new[81]	_	_
12-33	1940-1942	or	event[79]|abstract[80]	new[79]|new[80]	_	_
12-34	1943-1955	interruption	event[79]|abstract[80]|abstract[82]	new[79]|new[80]|new[82]	_	_
12-35	1956-1958	of	event[79]|abstract[80]|abstract[82]	new[79]|new[80]|new[82]	_	_
12-36	1959-1966	therapy	event[79]|abstract[80]|abstract[82]|abstract	new[79]|new[80]|new[82]|giv	coref	16-4[144_0]
12-37	1967-1969	or	event[79]|abstract[80]	new[79]|new[80]	_	_
12-38	1970-1974	even	event[79]|abstract[80]|abstract[84]	new[79]|new[80]|giv[84]	_	_
12-39	1975-1986	prophylaxis	event[79]|abstract[80]|abstract[84]	new[79]|new[80]|giv[84]	_	_
12-40	1987-1988	;	_	_	_	_
12-41	1989-1990	(	_	_	_	_
12-42	1991-1993	ii	_	_	_	_
12-43	1994-1995	)	_	_	_	_
12-44	1996-2007	sub-optimal	abstract[85]	new[85]	_	_
12-45	2008-2023	biodistribution	abstract[85]	new[85]	_	_
12-46	2024-2027	and	_	_	_	_
12-47	2028-2044	pharmacokinetics	place[86]	new[86]	_	_
12-48	2045-2046	,	place[86]	new[86]	_	_
12-49	2047-2059	particularly	place[86]|place[88]	new[86]|new[88]	_	_
12-50	2060-2062	in	place[86]|place[88]	new[86]|new[88]	_	_
12-51	2063-2072	reservoir	place[86]|place|place[88]	new[86]|new|new[88]	_	_
12-52	2073-2078	sites	place[86]|place[88]	new[86]|new[88]	_	_
12-53	2079-2081	or	place[86]	new[86]	_	_
12-54	2082-2089	mucosae	place[86]|animal[89]	new[86]|new[89]	_	_
12-55	2090-2098	involved	place[86]|animal[89]	new[86]|new[89]	_	_
12-56	2099-2101	in	place[86]|animal[89]	new[86]|new[89]	_	_
12-57	2102-2108	sexual	place[86]|animal[89]|event[90]	new[86]|new[89]|giv[90]	_	_
12-58	2109-2121	transmission	place[86]|animal[89]|event[90]	new[86]|new[89]|giv[90]	_	_
12-59	2122-2123	;	place[86]|animal[89]	new[86]|new[89]	_	_
12-60	2124-2125	(	place[86]|animal[89]	new[86]|new[89]	_	_
12-61	2126-2129	iii	place[86]|animal[89]	new[86]|new[89]	_	_
12-62	2130-2131	)	place[86]|animal[89]	new[86]|new[89]	_	_
12-63	2132-2135	the	place[86]|animal[89]|event[91]	new[86]|new[89]|new[91]	_	_
12-64	2136-2146	occurrence	place[86]|animal[89]|event[91]	new[86]|new[89]|new[91]	_	_
12-65	2147-2149	of	place[86]|animal[89]|event[91]	new[86]|new[89]|new[91]	_	_
12-66	2150-2155	viral	place[86]|animal[89]|event[91]|abstract[92]	new[86]|new[89]|new[91]|new[92]	_	_
12-67	2156-2166	resistance	place[86]|animal[89]|event[91]|abstract[92]	new[86]|new[89]|new[91]|new[92]	_	_
12-68	2167-2168	;	place[86]|animal[89]|event[91]	new[86]|new[89]|new[91]	_	_
12-69	2169-2170	(	place[86]|animal[89]|event[91]	new[86]|new[89]|new[91]	_	_
12-70	2171-2173	iv	place[86]|animal[89]|event[91]	new[86]|new[89]|new[91]	_	_
12-71	2174-2175	)	place[86]|animal[89]|event[91]	new[86]|new[89]|new[91]	_	_
12-72	2176-2187	troublesome	place[86]|animal[89]|abstract[93]	new[86]|new[89]|new[93]	_	_
12-73	2188-2196	regimens	place[86]|animal[89]|abstract[93]	new[86]|new[89]|new[93]	_	_
12-74	2197-2203	and/or	place[86]|animal[89]|abstract[93]	new[86]|new[89]|new[93]	_	_
12-75	2204-2208	drug	place[86]|animal[89]|abstract[93]|substance|abstract[95]|abstract[96]	new[86]|new[89]|new[93]|giv|new[95]|new[96]	coref|coref	12-140|15-41[141_95]
12-76	2209-2217	delivery	place[86]|animal[89]|abstract[93]|abstract[95]|abstract[96]	new[86]|new[89]|new[93]|new[95]|new[96]	_	_
12-77	2218-2224	routes	place[86]|animal[89]|abstract[93]|abstract[96]	new[86]|new[89]|new[93]|new[96]	_	_
12-78	2225-2229	that	place[86]|animal[89]|abstract[93]	new[86]|new[89]|new[93]	_	_
12-79	2230-2234	lead	place[86]|animal[89]|abstract[93]	new[86]|new[89]|new[93]	_	_
12-80	2235-2237	to	place[86]|animal[89]|abstract[93]	new[86]|new[89]|new[93]	_	_
12-81	2238-2242	poor	place[86]|animal[89]|abstract[93]|abstract[97]	new[86]|new[89]|new[93]|new[97]	_	_
12-82	2243-2252	adherence	place[86]|animal[89]|abstract[93]|abstract[97]	new[86]|new[89]|new[93]|new[97]	_	_
12-83	2253-2255	by	place[86]|animal[89]|abstract[93]|abstract[97]	new[86]|new[89]|new[93]|new[97]	_	_
12-84	2256-2270	patients/users	place[86]|animal[89]|abstract[93]|abstract[97]|person	new[86]|new[89]|new[93]|new[97]|new	_	_
12-85	2271-2272	;	abstract[93]	new[93]	_	_
12-86	2273-2274	(	abstract[93]	new[93]	_	_
12-87	2275-2276	v	abstract[93]	new[93]	_	_
12-88	2277-2278	)	abstract[93]	new[93]	_	_
12-89	2279-2282	low	abstract[99]	new[99]	_	_
12-90	2283-2292	stability	abstract[99]	new[99]	_	_
12-91	2293-2296	and	_	_	_	_
12-92	2297-2304	reduced	abstract[100]	new[100]	_	_
12-93	2305-2315	shelf-life	abstract[100]	new[100]	_	_
12-94	2316-2318	of	abstract[100]	new[100]	_	_
12-95	2319-2325	active	abstract[100]|object[101]	new[100]|new[101]	_	_
12-96	2326-2335	molecules	abstract[100]|object[101]	new[100]|new[101]	_	_
12-97	2336-2337	,	abstract[100]	new[100]	_	_
12-98	2338-2343	which	abstract[100]	new[100]	_	_
12-99	2344-2347	may	abstract[100]	new[100]	_	_
12-100	2348-2350	be	abstract[100]	new[100]	_	_
12-101	2351-2363	particularly	abstract[100]	new[100]	_	_
12-102	2364-2375	challenging	abstract[100]	new[100]	_	_
12-103	2376-2378	in	abstract[100]	new[100]	_	_
12-104	2379-2387	tropical	abstract[100]|abstract[102]	new[100]|new[102]	_	_
12-105	2388-2396	climates	abstract[100]|abstract[102]	new[100]|new[102]	_	_
12-106	2397-2400	and	abstract[100]	new[100]	_	_
12-107	2401-2413	low-resource	abstract[100]|place[103]	new[100]|new[103]	_	_
12-108	2414-2421	regions	abstract[100]|place[103]	new[100]|new[103]	_	_
12-109	2422-2429	lacking	abstract[100]|place[103]	new[100]|new[103]	_	_
12-110	2430-2438	adequate	abstract[100]|place[103]|place[105]	new[100]|new[103]|new[105]	_	_
12-111	2439-2451	refrigerated	abstract[100]|place[103]|place[105]	new[100]|new[103]|new[105]	_	_
12-112	2452-2464	distribution	abstract[100]|place[103]|abstract|place[105]	new[100]|new[103]|new|new[105]	_	_
12-113	2465-2473	channels	abstract[100]|place[103]|place[105]	new[100]|new[103]|new[105]	_	_
12-114	2474-2477	and	abstract[100]|place[103]	new[100]|new[103]	_	_
12-115	2478-2485	storage	abstract[100]|place[103]|place	new[100]|new[103]|new	_	_
12-116	2486-2487	;	_	_	_	_
12-117	2488-2489	(	_	_	_	_
12-118	2490-2492	vi	_	_	_	_
12-119	2493-2494	)	_	_	_	_
12-120	2495-2499	lack	abstract[107]	new[107]	_	_
12-121	2500-2502	of	abstract[107]	new[107]	_	_
12-122	2503-2511	suitable	abstract[107]|abstract[109]	new[107]|new[109]	_	_
12-123	2512-2518	dosage	abstract[107]|substance|abstract[109]	new[107]|new|new[109]	_	_
12-124	2519-2524	forms	abstract[107]|abstract[109]	new[107]|new[109]	_	_
12-125	2525-2528	for	abstract[107]|abstract[109]	new[107]|new[109]	_	_
12-126	2529-2539	particular	abstract[107]|abstract[109]|person[110]	new[107]|new[109]|new[110]	coref	12-147[114_110]
12-127	2540-2551	populations	abstract[107]|abstract[109]|person[110]	new[107]|new[109]|new[110]	_	_
12-128	2552-2553	(	_	_	_	_
12-129	2554-2558	e.g.	_	_	_	_
12-130	2559-2560	,	_	_	_	_
12-131	2561-2569	children	_	_	_	_
12-132	2570-2573	and	_	_	_	_
12-133	2574-2579	women	_	_	_	_
12-134	2580-2581	)	_	_	_	_
12-135	2582-2583	;	_	_	_	_
12-136	2584-2585	(	_	_	_	_
12-137	2586-2589	vii	_	_	_	_
12-138	2590-2591	)	_	_	_	_
12-139	2592-2598	costly	object[112]|abstract[113]	giv[112]|giv[113]	coref	14-4[126_112]
12-140	2599-2603	drug	substance|object[112]|abstract[113]	giv|giv[112]|giv[113]	coref	15-29
12-141	2604-2612	products	object[112]|abstract[113]	giv[112]|giv[113]	_	_
12-142	2613-2617	that	object[112]|abstract[113]	giv[112]|giv[113]	_	_
12-143	2618-2621	are	object[112]|abstract[113]	giv[112]|giv[113]	_	_
12-144	2622-2627	often	object[112]|abstract[113]	giv[112]|giv[113]	_	_
12-145	2628-2640	inaccessible	object[112]|abstract[113]	giv[112]|giv[113]	_	_
12-146	2641-2643	to	object[112]|abstract[113]	giv[112]|giv[113]	_	_
12-147	2644-2655	populations	object[112]|abstract[113]|person[114]	giv[112]|giv[113]|giv[114]	_	_
12-148	2656-2658	in	object[112]|abstract[113]|person[114]	giv[112]|giv[113]|giv[114]	_	_
12-149	2659-2663	need	object[112]|abstract[113]|person[114]|abstract[115]	giv[112]|giv[113]|giv[114]|new[115]	_	_
12-150	2664-2666	of	object[112]|abstract[113]|person[114]|abstract[115]	giv[112]|giv[113]|giv[114]|new[115]	_	_
12-151	2667-2686	therapy/prophylaxis	object[112]|abstract[113]|person[114]|abstract[115]|abstract	giv[112]|giv[113]|giv[114]|new[115]|giv	coref	12-170[120_0]
12-152	2687-2688	;	abstract[113]	giv[113]	_	_
12-153	2689-2692	and	abstract[113]	giv[113]	_	_
12-154	2693-2694	(	abstract[113]	giv[113]	_	_
12-155	2695-2699	viii	abstract[113]	giv[113]	_	_
12-156	2700-2701	)	abstract[113]	giv[113]	_	_
12-157	2702-2708	social	abstract[113]|abstract[117]	giv[113]|new[117]	_	_
12-158	2709-2712	and	abstract[113]|abstract[117]	giv[113]|new[117]	_	_
12-159	2713-2718	legal	abstract[113]|abstract[117]	giv[113]|new[117]	_	_
12-160	2719-2730	constraints	abstract[113]|abstract[117]	giv[113]|new[117]	_	_
12-161	2731-2740	resulting	abstract[113]|abstract[117]	giv[113]|new[117]	_	_
12-162	2741-2743	in	abstract[113]|abstract[117]	giv[113]|new[117]	_	_
12-163	2744-2748	poor	abstract[113]|abstract[117]|abstract[118]	giv[113]|new[117]|new[118]	_	_
12-164	2749-2755	access	abstract[113]|abstract[117]|abstract[118]	giv[113]|new[117]|new[118]	_	_
12-165	2756-2758	to	abstract[113]|abstract[117]	giv[113]|new[117]	_	_
12-166	2759-2762	and	abstract[113]|abstract[117]	giv[113]|new[117]	_	_
12-167	2763-2766	the	abstract[113]|abstract[117]|event[119]	giv[113]|new[117]|giv[119]	_	_
12-168	2767-2782	discontinuation	abstract[113]|abstract[117]|event[119]	giv[113]|new[117]|giv[119]	_	_
12-169	2783-2785	of	abstract[113]|abstract[117]|event[119]	giv[113]|new[117]|giv[119]	_	_
12-170	2786-2794	anti-HIV	abstract[113]|abstract[117]|event[119]|abstract[120]	giv[113]|new[117]|giv[119]|giv[120]	coref	17-19[152_120]
12-171	2795-2814	therapy/prophylaxis	abstract[113]|abstract[117]|event[119]|abstract[120]	giv[113]|new[117]|giv[119]|giv[120]	_	_
12-172	2815-2816	.	_	_	_	_

#Text=The response from the scientific community could not be more affirmative , and novel ideas and concepts have been emerging throughout the last decade or so .
13-1	2817-2820	The	abstract[121]	new[121]	_	_
13-2	2821-2829	response	abstract[121]	new[121]	_	_
13-3	2830-2834	from	abstract[121]	new[121]	_	_
13-4	2835-2838	the	abstract[121]|organization[122]	new[121]|new[122]	_	_
13-5	2839-2849	scientific	abstract[121]|organization[122]	new[121]|new[122]	_	_
13-6	2850-2859	community	abstract[121]|organization[122]	new[121]|new[122]	_	_
13-7	2860-2865	could	_	_	_	_
13-8	2866-2869	not	_	_	_	_
13-9	2870-2872	be	_	_	_	_
13-10	2873-2877	more	_	_	_	_
13-11	2878-2889	affirmative	_	_	_	_
13-12	2890-2891	,	_	_	_	_
13-13	2892-2895	and	_	_	_	_
13-14	2896-2901	novel	abstract[123]	new[123]	_	_
13-15	2902-2907	ideas	abstract[123]	new[123]	_	_
13-16	2908-2911	and	_	_	_	_
13-17	2912-2920	concepts	abstract	new	_	_
13-18	2921-2925	have	_	_	_	_
13-19	2926-2930	been	_	_	_	_
13-20	2931-2939	emerging	_	_	_	_
13-21	2940-2950	throughout	_	_	_	_
13-22	2951-2954	the	time[125]	new[125]	_	_
13-23	2955-2959	last	time[125]	new[125]	_	_
13-24	2960-2966	decade	time[125]	new[125]	_	_
13-25	2967-2969	or	_	_	_	_
13-26	2970-2972	so	_	_	_	_
13-27	2973-2974	.	_	_	_	_

#Text=More important , innovative products are now under development , holding great promise for mitigating many of the challenges identified above .
14-1	2975-2979	More	_	_	_	_
14-2	2980-2989	important	_	_	_	_
14-3	2990-2991	,	_	_	_	_
14-4	2992-3002	innovative	object[126]	giv[126]	coref	15-28[138_126]
14-5	3003-3011	products	object[126]	giv[126]	_	_
14-6	3012-3015	are	_	_	_	_
14-7	3016-3019	now	_	_	_	_
14-8	3020-3025	under	_	_	_	_
14-9	3026-3037	development	_	_	_	_
14-10	3038-3039	,	_	_	_	_
14-11	3040-3047	holding	_	_	_	_
14-12	3048-3053	great	abstract[127]	new[127]	_	_
14-13	3054-3061	promise	abstract[127]	new[127]	_	_
14-14	3062-3065	for	abstract[127]	new[127]	_	_
14-15	3066-3076	mitigating	abstract[127]	new[127]	_	_
14-16	3077-3081	many	abstract[127]	new[127]	_	_
14-17	3082-3084	of	_	_	_	_
14-18	3085-3088	the	abstract[128]	giv[128]	_	_
14-19	3089-3099	challenges	abstract[128]	giv[128]	_	_
14-20	3100-3110	identified	abstract[128]	giv[128]	_	_
14-21	3111-3116	above	abstract[128]	giv[128]	_	_
14-22	3117-3118	.	_	_	_	_

#Text=This Special Issue presents an exciting series of reviews and original research articles from eminent scientists in academia and different nonprofit organizations involved in the development of antiretroviral drug products , focusing mainly on novel strategies for the formulation and delivery of anti-HIV compounds .
15-1	3119-3123	This	abstract[129]	new[129]	coref	18-1[159_129]
15-2	3124-3131	Special	abstract[129]	new[129]	_	_
15-3	3132-3137	Issue	abstract[129]	new[129]	_	_
15-4	3138-3146	presents	_	_	_	_
15-5	3147-3149	an	abstract[130]	new[130]	_	_
15-6	3150-3158	exciting	abstract[130]	new[130]	_	_
15-7	3159-3165	series	abstract[130]	new[130]	_	_
15-8	3166-3168	of	abstract[130]	new[130]	_	_
15-9	3169-3176	reviews	abstract[130]|abstract	new[130]|new	_	_
15-10	3177-3180	and	abstract[130]	new[130]	_	_
15-11	3181-3189	original	abstract[130]|abstract[132]	new[130]|new[132]	_	_
15-12	3190-3198	research	abstract[130]|abstract[132]	new[130]|new[132]	_	_
15-13	3199-3207	articles	abstract[130]|abstract[132]	new[130]|new[132]	_	_
15-14	3208-3212	from	abstract[130]|abstract[132]	new[130]|new[132]	_	_
15-15	3213-3220	eminent	abstract[130]|abstract[132]|person[133]	new[130]|new[132]|new[133]	_	_
15-16	3221-3231	scientists	abstract[130]|abstract[132]|person[133]	new[130]|new[132]|new[133]	_	_
15-17	3232-3234	in	abstract[130]|abstract[132]|person[133]	new[130]|new[132]|new[133]	_	_
15-18	3235-3243	academia	abstract[130]|abstract[132]|person[133]|abstract	new[130]|new[132]|new[133]|new	_	_
15-19	3244-3247	and	abstract[130]|abstract[132]|person[133]	new[130]|new[132]|new[133]	_	_
15-20	3248-3257	different	abstract[130]|abstract[132]|person[133]|organization[135]	new[130]|new[132]|new[133]|new[135]	_	_
15-21	3258-3267	nonprofit	abstract[130]|abstract[132]|person[133]|organization[135]	new[130]|new[132]|new[133]|new[135]	_	_
15-22	3268-3281	organizations	abstract[130]|abstract[132]|person[133]|organization[135]	new[130]|new[132]|new[133]|new[135]	_	_
15-23	3282-3290	involved	abstract[130]|abstract[132]|person[133]	new[130]|new[132]|new[133]	_	_
15-24	3291-3293	in	abstract[130]|abstract[132]|person[133]	new[130]|new[132]|new[133]	_	_
15-25	3294-3297	the	abstract[130]|abstract[132]|person[133]|abstract[136]	new[130]|new[132]|new[133]|new[136]	_	_
15-26	3298-3309	development	abstract[130]|abstract[132]|person[133]|abstract[136]	new[130]|new[132]|new[133]|new[136]	_	_
15-27	3310-3312	of	abstract[130]|abstract[132]|person[133]|abstract[136]	new[130]|new[132]|new[133]|new[136]	_	_
15-28	3313-3327	antiretroviral	abstract[130]|abstract[132]|person[133]|abstract[136]|object[138]	new[130]|new[132]|new[133]|new[136]|giv[138]	coref	17-31[156_138]
15-29	3328-3332	drug	abstract[130]|abstract[132]|person[133]|abstract[136]|substance|object[138]	new[130]|new[132]|new[133]|new[136]|giv|giv[138]	coref	17-22
15-30	3333-3341	products	abstract[130]|abstract[132]|person[133]|abstract[136]|object[138]	new[130]|new[132]|new[133]|new[136]|giv[138]	_	_
15-31	3342-3343	,	_	_	_	_
15-32	3344-3352	focusing	_	_	_	_
15-33	3353-3359	mainly	_	_	_	_
15-34	3360-3362	on	_	_	_	_
15-35	3363-3368	novel	abstract[139]	new[139]	coref	18-18[165_139]
15-36	3369-3379	strategies	abstract[139]	new[139]	_	_
15-37	3380-3383	for	abstract[139]	new[139]	_	_
15-38	3384-3387	the	abstract[139]|abstract[140]	new[139]|new[140]	_	_
15-39	3388-3399	formulation	abstract[139]|abstract[140]	new[139]|new[140]	_	_
15-40	3400-3403	and	abstract[139]	new[139]	_	_
15-41	3404-3412	delivery	abstract[139]|abstract[141]	new[139]|giv[141]	coref	17-22[154_141]
15-42	3413-3415	of	abstract[139]|abstract[141]	new[139]|giv[141]	_	_
15-43	3416-3424	anti-HIV	abstract[139]|abstract[141]|substance[142]	new[139]|giv[141]|new[142]	_	_
15-44	3425-3434	compounds	abstract[139]|abstract[141]|substance[142]	new[139]|giv[141]|new[142]	_	_
15-45	3435-3436	.	_	_	_	_

#Text=Innovative approaches towards improved gene therapy and immunotherapy are also addressed .
16-1	3437-3447	Innovative	abstract[143]	giv[143]	coref	19-19[178_143]
16-2	3448-3458	approaches	abstract[143]	giv[143]	_	_
16-3	3459-3466	towards	abstract[143]	giv[143]	_	_
16-4	3467-3475	improved	abstract[143]|abstract[144]|abstract[145]	giv[143]|giv[144]|giv[145]	coref|coref	18-28[169_144]|18-28[170_145]
16-5	3476-3480	gene	abstract[143]|abstract[144]|abstract[145]	giv[143]|giv[144]|giv[145]	_	_
16-6	3481-3488	therapy	abstract[143]|abstract[144]|abstract[145]	giv[143]|giv[144]|giv[145]	_	_
16-7	3489-3492	and	abstract[143]|abstract[145]	giv[143]|giv[145]	_	_
16-8	3493-3506	immunotherapy	abstract[143]|abstract[145]|abstract	giv[143]|giv[145]|new	_	_
16-9	3507-3510	are	_	_	_	_
16-10	3511-3515	also	_	_	_	_
16-11	3516-3525	addressed	_	_	_	_
16-12	3526-3527	.	_	_	_	_

#Text=The presented reports provide not only interesting overviews and opinion on recent developments in the broad field of antiretroviral therapy/prophylaxis and drug delivery , but also describe the development of new products that are currently tracked for clinical testing .
17-1	3528-3531	The	abstract[147]	new[147]	_	_
17-2	3532-3541	presented	abstract[147]	new[147]	_	_
17-3	3542-3549	reports	abstract[147]	new[147]	_	_
17-4	3550-3557	provide	_	_	_	_
17-5	3558-3561	not	_	_	_	_
17-6	3562-3566	only	abstract[148]	new[148]	_	_
17-7	3567-3578	interesting	abstract[148]	new[148]	_	_
17-8	3579-3588	overviews	abstract[148]	new[148]	_	_
17-9	3589-3592	and	_	_	_	_
17-10	3593-3600	opinion	abstract[149]	new[149]	_	_
17-11	3601-3603	on	abstract[149]	new[149]	_	_
17-12	3604-3610	recent	abstract[149]|abstract[150]	new[149]|new[150]	_	_
17-13	3611-3623	developments	abstract[149]|abstract[150]	new[149]|new[150]	_	_
17-14	3624-3626	in	abstract[149]|abstract[150]	new[149]|new[150]	_	_
17-15	3627-3630	the	abstract[149]|abstract[150]|abstract[151]	new[149]|new[150]|giv[151]	coref	20-1[184_151]
17-16	3631-3636	broad	abstract[149]|abstract[150]|abstract[151]	new[149]|new[150]|giv[151]	_	_
17-17	3637-3642	field	abstract[149]|abstract[150]|abstract[151]	new[149]|new[150]|giv[151]	_	_
17-18	3643-3645	of	abstract[149]|abstract[150]|abstract[151]	new[149]|new[150]|giv[151]	_	_
17-19	3646-3660	antiretroviral	abstract[149]|abstract[150]|abstract[151]|abstract[152]	new[149]|new[150]|giv[151]|giv[152]	_	_
17-20	3661-3680	therapy/prophylaxis	abstract[149]|abstract[150]|abstract[151]|abstract[152]	new[149]|new[150]|giv[151]|giv[152]	_	_
17-21	3681-3684	and	abstract[149]|abstract[150]|abstract[151]	new[149]|new[150]|giv[151]	_	_
17-22	3685-3689	drug	abstract[149]|abstract[150]|abstract[151]|substance|abstract[154]	new[149]|new[150]|giv[151]|giv|giv[154]	_	_
17-23	3690-3698	delivery	abstract[149]|abstract[150]|abstract[151]|abstract[154]	new[149]|new[150]|giv[151]|giv[154]	_	_
17-24	3699-3700	,	_	_	_	_
17-25	3701-3704	but	_	_	_	_
17-26	3705-3709	also	_	_	_	_
17-27	3710-3718	describe	_	_	_	_
17-28	3719-3722	the	event[155]	new[155]	_	_
17-29	3723-3734	development	event[155]	new[155]	_	_
17-30	3735-3737	of	event[155]	new[155]	_	_
17-31	3738-3741	new	event[155]|object[156]	new[155]|giv[156]	_	_
17-32	3742-3750	products	event[155]|object[156]	new[155]|giv[156]	_	_
17-33	3751-3755	that	event[155]|object[156]	new[155]|giv[156]	_	_
17-34	3756-3759	are	event[155]|object[156]	new[155]|giv[156]	_	_
17-35	3760-3769	currently	event[155]|object[156]	new[155]|giv[156]	_	_
17-36	3770-3777	tracked	event[155]|object[156]	new[155]|giv[156]	_	_
17-37	3778-3781	for	event[155]|object[156]	new[155]|giv[156]	_	_
17-38	3782-3790	clinical	event[155]|object[156]|abstract[157]	new[155]|giv[156]|new[157]	_	_
17-39	3791-3798	testing	event[155]|object[156]|abstract[157]	new[155]|giv[156]|new[157]	_	_
17-40	3799-3800	.	_	_	_	_

#Text=The Special Issue starts with an interesting review by Tsukamoto at Kindai University , Japan , on strategies explored for curing HIV infection using a combination of gene therapy and host immunization .
18-1	3801-3804	The	abstract[159]	giv[159]	_	_
18-2	3805-3812	Special	person|abstract[159]	new|giv[159]	_	_
18-3	3813-3818	Issue	abstract[159]	giv[159]	_	_
18-4	3819-3825	starts	_	_	_	_
18-5	3826-3830	with	_	_	_	_
18-6	3831-3833	an	abstract[160]	new[160]	coref	20-20[190_160]
18-7	3834-3845	interesting	abstract[160]	new[160]	_	_
18-8	3846-3852	review	abstract[160]	new[160]	_	_
18-9	3853-3855	by	abstract[160]	new[160]	_	_
18-10	3856-3865	Tsukamoto	abstract[160]|person[161]	new[160]|new[161]	_	_
18-11	3866-3868	at	abstract[160]|person[161]	new[160]|new[161]	_	_
18-12	3869-3875	Kindai	abstract[160]|person[161]|person|organization[163]	new[160]|new[161]|new|new[163]	coref	20-11[187_163]
18-13	3876-3886	University	abstract[160]|person[161]|organization[163]	new[160]|new[161]|new[163]	_	_
18-14	3887-3888	,	abstract[160]|person[161]|organization[163]	new[160]|new[161]|new[163]	_	_
18-15	3889-3894	Japan	abstract[160]|person[161]|organization[163]|place	new[160]|new[161]|new[163]|new	_	_
18-16	3895-3896	,	abstract[160]	new[160]	_	_
18-17	3897-3899	on	abstract[160]	new[160]	_	_
18-18	3900-3910	strategies	abstract[160]|abstract[165]	new[160]|giv[165]	_	_
18-19	3911-3919	explored	abstract[160]|abstract[165]	new[160]|giv[165]	_	_
18-20	3920-3923	for	_	_	_	_
18-21	3924-3930	curing	_	_	_	_
18-22	3931-3934	HIV	abstract|abstract[167]	giv|giv[167]	coref	20-34
18-23	3935-3944	infection	abstract[167]	giv[167]	_	_
18-24	3945-3950	using	_	_	_	_
18-25	3951-3952	a	abstract[168]	giv[168]	_	_
18-26	3953-3964	combination	abstract[168]	giv[168]	_	_
18-27	3965-3967	of	abstract[168]	giv[168]	_	_
18-28	3968-3972	gene	abstract[168]|abstract[169]|abstract[170]	giv[168]|giv[169]|giv[170]	coref	21-14[199_169]
18-29	3973-3980	therapy	abstract[168]|abstract[169]|abstract[170]	giv[168]|giv[169]|giv[170]	_	_
18-30	3981-3984	and	abstract[168]|abstract[170]	giv[168]|giv[170]	_	_
18-31	3985-3989	host	abstract[168]|abstract[170]|person|abstract[172]	giv[168]|giv[170]|new|new[172]	coref	19-11[175_172]
18-32	3990-4002	immunization	abstract[168]|abstract[170]|abstract[172]	giv[168]|giv[170]|new[172]	_	_
18-33	4003-4004	.	_	_	_	_

#Text=In particular , the author emphasizes the possible role of anti-HIV intracellular immunization using gene silencing , among other approaches , in the protection of bone marrow hematopoietic stem/progenitor cells .
19-1	4005-4007	In	_	_	_	_
19-2	4008-4018	particular	_	_	_	_
19-3	4019-4020	,	_	_	_	_
19-4	4021-4024	the	person[173]	new[173]	_	_
19-5	4025-4031	author	person[173]	new[173]	_	_
19-6	4032-4042	emphasizes	_	_	_	_
19-7	4043-4046	the	abstract[174]	new[174]	_	_
19-8	4047-4055	possible	abstract[174]	new[174]	_	_
19-9	4056-4060	role	abstract[174]	new[174]	_	_
19-10	4061-4063	of	abstract[174]	new[174]	_	_
19-11	4064-4072	anti-HIV	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
19-12	4073-4086	intracellular	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
19-13	4087-4099	immunization	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
19-14	4100-4105	using	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
19-15	4106-4110	gene	abstract[174]|abstract[175]|abstract|abstract[177]	new[174]|giv[175]|new|new[177]	coref	21-15
19-16	4111-4120	silencing	abstract[174]|abstract[175]|abstract[177]	new[174]|giv[175]|new[177]	_	_
19-17	4121-4122	,	abstract[174]	new[174]	_	_
19-18	4123-4128	among	abstract[174]	new[174]	_	_
19-19	4129-4134	other	abstract[174]|abstract[178]	new[174]|giv[178]	_	_
19-20	4135-4145	approaches	abstract[174]|abstract[178]	new[174]|giv[178]	_	_
19-21	4146-4147	,	abstract[174]	new[174]	_	_
19-22	4148-4150	in	abstract[174]	new[174]	_	_
19-23	4151-4154	the	abstract[174]|abstract[179]	new[174]|new[179]	_	_
19-24	4155-4165	protection	abstract[174]|abstract[179]	new[174]|new[179]	_	_
19-25	4166-4168	of	abstract[174]|abstract[179]	new[174]|new[179]	_	_
19-26	4169-4173	bone	abstract[174]|abstract[179]|object|animal[181]|object[183]	new[174]|new[179]|new|new[181]|new[183]	coref	21-19[200_183]
19-27	4174-4180	marrow	abstract[174]|abstract[179]|animal[181]|object[183]	new[174]|new[179]|new[181]|new[183]	_	_
19-28	4181-4194	hematopoietic	abstract[174]|abstract[179]|substance[182]|object[183]	new[174]|new[179]|new[182]|new[183]	_	_
19-29	4195-4210	stem/progenitor	abstract[174]|abstract[179]|substance[182]|object[183]	new[174]|new[179]|new[182]|new[183]	_	_
19-30	4211-4216	cells	abstract[174]|abstract[179]|object[183]	new[174]|new[179]|new[183]	_	_
19-31	4217-4218	.	_	_	_	_

#Text=Still in the same field , Düzgüneş and Konopka at the University of the Pacific , USA , contributed a stimulating review on a potential strategy for the eradication of cellular reservoirs of HIV .
20-1	4219-4224	Still	abstract[184]	giv[184]	_	_
20-2	4225-4227	in	abstract[184]	giv[184]	_	_
20-3	4228-4231	the	abstract[184]	giv[184]	_	_
20-4	4232-4236	same	abstract[184]	giv[184]	_	_
20-5	4237-4242	field	abstract[184]	giv[184]	_	_
20-6	4243-4244	,	_	_	_	_
20-7	4245-4253	Düzgüneş	person	new	_	_
20-8	4254-4257	and	_	_	_	_
20-9	4258-4265	Konopka	person[186]	new[186]	_	_
20-10	4266-4268	at	person[186]	new[186]	_	_
20-11	4269-4272	the	person[186]|organization[187]	new[186]|giv[187]	_	_
20-12	4273-4283	University	person[186]|organization[187]	new[186]|giv[187]	_	_
20-13	4284-4286	of	person[186]|organization[187]	new[186]|giv[187]	_	_
20-14	4287-4290	the	person[186]|organization[187]|place[188]	new[186]|giv[187]|new[188]	_	_
20-15	4291-4298	Pacific	person[186]|organization[187]|place[188]	new[186]|giv[187]|new[188]	_	_
20-16	4299-4300	,	person[186]|organization[187]|place[188]	new[186]|giv[187]|new[188]	_	_
20-17	4301-4304	USA	person[186]|organization[187]|place[188]|place	new[186]|giv[187]|new[188]|new	_	_
20-18	4305-4306	,	_	_	_	_
20-19	4307-4318	contributed	_	_	_	_
20-20	4319-4320	a	abstract[190]	giv[190]	_	_
20-21	4321-4332	stimulating	abstract[190]	giv[190]	_	_
20-22	4333-4339	review	abstract[190]	giv[190]	_	_
20-23	4340-4342	on	abstract[190]	giv[190]	_	_
20-24	4343-4344	a	abstract[190]|abstract[191]	giv[190]|new[191]	_	_
20-25	4345-4354	potential	abstract[190]|abstract[191]	giv[190]|new[191]	_	_
20-26	4355-4363	strategy	abstract[190]|abstract[191]	giv[190]|new[191]	_	_
20-27	4364-4367	for	abstract[190]|abstract[191]	giv[190]|new[191]	_	_
20-28	4368-4371	the	abstract[190]|abstract[191]|event[192]	giv[190]|new[191]|new[192]	_	_
20-29	4372-4383	eradication	abstract[190]|abstract[191]|event[192]	giv[190]|new[191]|new[192]	_	_
20-30	4384-4386	of	abstract[190]|abstract[191]|event[192]	giv[190]|new[191]|new[192]	_	_
20-31	4387-4395	cellular	abstract[190]|abstract[191]|event[192]|substance[193]	giv[190]|new[191]|new[192]|new[193]	_	_
20-32	4396-4406	reservoirs	abstract[190]|abstract[191]|event[192]|substance[193]	giv[190]|new[191]|new[192]|new[193]	_	_
20-33	4407-4409	of	abstract[190]|abstract[191]|event[192]|substance[193]	giv[190]|new[191]|new[192]|new[193]	_	_
20-34	4410-4413	HIV	abstract[190]|abstract[191]|event[192]|substance[193]|abstract	giv[190]|new[191]|new[192]|new[193]|giv	_	_
20-35	4414-4415	.	_	_	_	_

#Text=This thought-provoking piece explores how such an objective could be achieved by using suicide gene therapy for killing HIV-infected cells , excision of chromosome-integrated viral DNA , and cytotoxic liposomes targeted to latency-reversed HIV-infected cells .
21-1	4416-4420	This	abstract[195]	new[195]	_	_
21-2	4421-4438	thought-provoking	abstract[195]	new[195]	_	_
21-3	4439-4444	piece	abstract[195]	new[195]	_	_
21-4	4445-4453	explores	_	_	_	_
21-5	4454-4457	how	_	_	_	_
21-6	4458-4462	such	abstract[196]	new[196]	_	_
21-7	4463-4465	an	abstract[196]	new[196]	_	_
21-8	4466-4475	objective	abstract[196]	new[196]	_	_
21-9	4476-4481	could	_	_	_	_
21-10	4482-4484	be	_	_	_	_
21-11	4485-4493	achieved	_	_	_	_
21-12	4494-4496	by	_	_	_	_
21-13	4497-4502	using	_	_	_	_
21-14	4503-4510	suicide	event|abstract[199]	new|giv[199]	_	_
21-15	4511-4515	gene	abstract|abstract[199]	giv|giv[199]	_	_
21-16	4516-4523	therapy	abstract[199]	giv[199]	_	_
21-17	4524-4527	for	_	_	_	_
21-18	4528-4535	killing	_	_	_	_
21-19	4536-4548	HIV-infected	object[200]	giv[200]	coref	21-33[204_200]
21-20	4549-4554	cells	object[200]	giv[200]	_	_
21-21	4555-4556	,	_	_	_	_
21-22	4557-4565	excision	event[201]	new[201]	_	_
21-23	4566-4568	of	event[201]	new[201]	_	_
21-24	4569-4590	chromosome-integrated	event[201]|substance[202]	new[201]|new[202]	_	_
21-25	4591-4596	viral	event[201]|substance[202]	new[201]|new[202]	_	_
21-26	4597-4600	DNA	event[201]|substance[202]	new[201]|new[202]	_	_
21-27	4601-4602	,	_	_	_	_
21-28	4603-4606	and	_	_	_	_
21-29	4607-4616	cytotoxic	substance[203]	new[203]	_	_
21-30	4617-4626	liposomes	substance[203]	new[203]	_	_
21-31	4627-4635	targeted	substance[203]	new[203]	_	_
21-32	4636-4638	to	substance[203]	new[203]	_	_
21-33	4639-4655	latency-reversed	substance[203]|object[204]	new[203]|giv[204]	_	_
21-34	4656-4668	HIV-infected	substance[203]|object[204]	new[203]|giv[204]	_	_
21-35	4669-4674	cells	substance[203]|object[204]	new[203]|giv[204]	_	_
21-36	4675-4676	.	_	_	_	_
